Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 15/20 | 0.68 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.64 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17084283 | 1.00 | NOD1 (0.68) | NOD1SLC6A5GNAI3GNAO1GNAI1 | |
| SCHEMBL15177658 | 0.90 | NOD1 (0.61) | NOD1SLC6A5GNAI3GNAO1GNAI1 | |
| SCHEMBL7196452 | 0.88 | NOD1 (0.81) | NOD1SLC6A5ITGB3ITGA2BGLP1R | |
| SCHEMBL4647979 | 0.88 | GNAI3 (0.64) | NOD1SLC6A5GNAI3GNAO1GNAI1 | |
| SCHEMBL4647986 | 0.88 | GNAI3 (0.64) | NOD1SLC6A5GNAI3GNAO1GNAI1 | |
| SCHEMBL5491543 | 0.88 | GNAI3 (0.64) | NOD1SLC6A5GNAI3GNAO1GNAI1 | |
| Lysine SCHEMBL16863679 | 0.87 | NOD1 (0.81) | NOD1SLC6A5ITGB3ITGA2B | |
| Lysine SCHEMBL29155849 | 0.86 | NOD1 (0.75) | NOD1SLC6A5ITGB3ITGA2B | |
| Lysine SCHEMBL11308550 | 0.86 | NOD1 (0.75) | NOD1SLC6A5ITGB3ITGA2B | |
| Lysine SCHEMBL28321657 | 0.86 | NOD1 (0.75) | NOD1SLC6A5ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9587005-B2 | Glucagon analogs exhibiting GIP receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160115215-A1 | Glucagon Analogs Exhibiting GIP Receptor Activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-04-28 | — | — | US | disclosed |
| US-9249206-B2 | Glucagon analogs exhibiting GIP receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150259393-A1 | Glucagon Analogs Exhibiting GIP Receptor Activity | UNIV INDIANA RES & TECH CORP (US) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259393-A1 | Glucagon Analogs Exhibiting GIP Receptor Activity | GLP1R, GIPR, GCGR | NOD1 1966/4885SLC6A5 2805/4885GNAI3 134/4885 |
| US-20160115215-A1 | Glucagon Analogs Exhibiting GIP Receptor Activity | GLP1R, GIPR, GCGR | NOD1 1966/4885SLC6A5 2805/4885GNAI3 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.